August 10, 2018
Researchers from the Icahn School of Medicine at Mount Sinai say they have developed a RNA and DNA sequencing platform that benefits late-stage and drug-resistant multiple myeloma patients by determining which drugs would work best for them. The team described its methodology (“Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach”) in JCO Precision...
Continue Reading
Lenalidomide maintenance improved PFS and OS among patients with newly diagnosed multiple myeloma compared with other maintenance treatments, according to results from a network meta-analysis. “The continuous therapy approach has been evaluated extensively in patients with newly diagnosed multiple myeloma, across age groups and treatment strategies upfront, in several trials with different designs,” Francesca Gay, MD,...
Continue Reading
A high level of resilience—or a person’s ability to adapt to adversity—was associated with a better mental and physical health-related quality of life (HRQOL) among patients with multiple myeloma and its precursor diseases, according to the results of a study published in BMJ Open. Early stages of multiple myeloma are usually asymptomatic, but survivors of myeloma often deal...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand